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of Neurology, Thomas Jefferson University, Philadelphia, PA, United States, 3 Department of Clinical Laboratory, Key Clinical
Laboratory of Henan Province, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China, 4 Henan Province
Chinese Medicine Research Institute, Zhengzhou, China, 5 Henan Province Engineering Laboratory for Clinical Evaluation
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Matrine (MAT), a quinolizidine alkaloid component derived from the root of Sophora
flavescens, suppresses experimental autoimmune encephalomyelitis (EAE), the animal
model of multiple sclerosis (MS), by inducing the production of immunomodulatory
molecules, e.g., IL-10. In an effort to find the upstream pathway(s) of the mechanism
underlying these effects, we have tested certain upregulated immunomodulatory
molecules. Among them, we found increased levels of IL-27 and IFN-β, one of the
first-line MS therapies. Indeed, while low levels of IFN-β production in sera and type
I interferon receptor (IFNAR1) expression in spinal cord of saline-treated control EAE
mice were detected, they were significantly increased after MAT treatment. Increased
numbers of CD11b+IFN-β+ microglia/infiltrating macrophages were observed in the
CNS of MAT-treated mice. The key role of IFN-β induction in the suppressive effect
of MAT on EAE was further verified by administration of anti-IFN-β neutralizing antibody,
which largely reversed the therapeutic effect of MAT. Further, we found that, while MAT
treatment induced production of IL-27 and IL-10 by CNS microglia/macrophages, this
effect was significantly reduced by IFN-β neutralizing antibody. Finally, the role of IFN-β
in MAT-induced IL-27 and IL-10 production was further confirmed in human monocytes
in vitro. Together, our study demonstrates that MAT exerts its therapeutic effect in EAE
through an IFN-β/IL-27/IL-10 pathway, and is likely a novel, safe, low-cost, and effective
therapy as an alternative to exogenous IFN-β for MS.
Keywords: matrine, multiple sclerosis, experimental autoimmune encephalomyelitis, IFN-β, IL-10, IL-27
INTRODUCTION
Multiple sclerosis (MS) and its animal model, experimental autoimmune encephalomyelitis (EAE),
are chronic inflammatory demyelinating diseases of the central nervous system (CNS) (1, 2). The
pathological features of MS are immune system imbalance, CNS inflammation, demyelination and
neuro-axonal damage (3–6). Myelin-reactive Th1 and Th17 cells are activated in the periphery and
infiltrate into the CNS, along with B cells, macrophages, dendritic cells and neutrophils. In the
CNS, these cells produce proinflammatory cytokines IFN-γ, IL-17, GM-CSF, and IL-23, activate
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microglia, and promote cell- and antibody-mediated immunity.
In contrast, immunoregulatory cytokines, such as IL-4, IL-10,
and IL-27, may be protective (1, 2). The effectiveness of current
therapies is limited (7, 8). Novel therapies for MS that are more
effective, and with fewer side effects than those currently in use
are, thus, crucially required.
Matrine (MAT), a quinolizidine alkaloid component
extracted from the root of Sophora flavescens, has been shown
to have anti-viral, immunoregulatory, anti-inflammatory,
anti-allergic and anti-tumor effects (9). We have previously
reported that MAT decreased clinical EAE severity, reduced
CNS inflammatory infiltration and demyelination, inhibited
production of inflammatory cytokines/chemokines, and
promoted the production of anti-inflammatory molecules such
as IL-4 and IL-10 (10). In addition, MAT promoted regeneration
of injured myelin sheaths by inhibiting the pathway of nerve
regeneration induced by Nogo-A (11). These results suggested
that MAT had significant anti-inflammatory potential for the
treatment of EAE/MS. However, the mechanisms underlying
these effects are still unknown.
To define the mechanism underlying MAT action in EAE
suppression, we tested certain known upstream signaling
pathways that regulate IL-10 expression in the CNS and
splenocytes of MAT-treated EAE mice. Among those molecules
upregulated, IFN-β was of high interest, given its effect in IL-
10 induction (12–14) and as a first-line therapy for MS (7,
8). IFN-β suppresses EAE, and its induction is beneficial in
treatment of autoimmune neuroinflammation (15). The key role
of IFN-β induction in the effect of MAT treatment in EAE was
further confirmed by neutralizing antibody in vivo and in human
monocytes in vitro.
MATERIALS AND METHODS
Animals, EAE Induction and Evaluation
Female C57BL/6 mice, 8–10 weeks old, were purchased from
the Beijing HFK Bioscience Co., Ltd., (Beijing, China), and
bred in specific pathogen-free conditions at the Henan Province
Traditional Chinese Medicine Research Institute, China. All
experimental procedures and protocols were approved by the
Bioethics Committee of Zhengzhou University and followed the
institutional guidelines and regulations. Every effort was made to
reduce animal suffering.
EAE was induced as described previously (16). Myelin
oligodendrocyte glycoprotein 35–55 (MOG35-55) peptide
lyophilized powder (Invitrogen, California state, United States)
was diluted to 3 mg/ml with 0.1 M PBS, emulsified with the
same volume of complete Freud’s adjuvant (CFA) (Sigma, St.
Louis, MO, United States) containing 4 mg/ml heat-killed
mycobacterium tuberculosis H37RA (Becton, Dickinson
and Company, NJ, United States). The mice were injected
subcutaneously at four separate points on the back with
200 µl of antigen emulsion. In addition, mice were injected
intraperitoneally (i.p.) with 200 ng/100 µl of pertussis toxin
(Sigma-Aldrich, Brøndby, Denmark) at the time of immunization
and 48 h later. Clinical signs of EAE were scored daily by two
researchers in a blind fashion as follows: 0 = no clinical score,
1 = loss of tail tone, 2 = hind limb weakness, 3 = hind limb
paralysis, 4 = forelimb paralysis, 5 = moribund or death.
A cumulative clinical score was calculated for each mouse
by adding the daily scores from the day of onset until the
end of treatment.
MAT and Neutralizing IFN-β Monoclonal
Antibody (mAb) Treatment
Immunized mice were randomly divided into two groups (n = 10
each group): (1) Saline: Immunized mice received 100 µl normal
saline per day i.p. from day 7 post immunization (p.i.). (2) MAT:
Immunized mice were injected i.p. with 150 mg/kg (20 ml/kg)
in 100 µl normal saline per day MAT (Jiangsu Chia-tai Tianqing
Pharmaceutical Co., Jiangsu, China) from day 7 p.i.
The role of IFN-β in MAT’s effect was further studied by
neutralizing this cytokine with monoclonal antibodies. Briefly,
immunized mice were randomly divided into four groups
(n = 10 each group). (1) MAT alone: Immunized mice received
150 mg/kg (20 ml/kg) in 100 µl normal saline per day i.p.
injection of MAT, starting from day 7 p.i. (2) Anti-IFN-β alone:
Immunized mice received 250 µg/kg (10 ml/kg) neutralizing
IFN-β mAb in 100 µl normal saline (Abcam, Cambridge,
United Kingdom) on days 12 and 14 p.i. (at EAE onset). (3)
MAT + anti-IFN-β: Immunized mice received IFN-β mAb and
MAT as described in Groups 1 and 2 above. (4) Saline alone:
Immunized mice that received 100 µl normal saline i.p. per day
from day 7 p.i. served as untreated control.
Isolation of Human Monocytes, MAT
Treatment and Cytokine Production
Blood samples were collected from healthy individuals and the
peripheral blood mononuclear cells (PBMCs) were enriched
after centrifugation in Ficoll gradient. CD14+ monocytes
were positively isolated using microbeads following the
manufacturer’s instructions (Miltenyi Biotec). One million cells
were seeded in 24 well plates in Iscove’s Modified Dulbecco
Medium (IMDM) supplemented with 10% Fetal Bovine Serum,
1X Glutamine/Streptomycin/Penicillin (Gibco) and 1X β-
mercaptoethanol (Gibco). To induce activation of monocytes,
cells were treated with 500 ng/ml of lipopolysaccharide (LPS,
Sigma-Aldrich) at 37◦C in the presence or absence of MAT
(100 µM). A total of 18 h later, supernatants were collected and
kept at−20◦C until used in ELISA assay.
Histopathological Evaluation
On day 19 p.i., mice were sacrificed and perfused with
normal saline. Lumbar enlargements of the spinal cords were
quickly removed, fixed with 4% paraformaldehyde, neutral-
buffered formalin, and embedded in paraffin. Inflammatory
infiltration was determined by hematoxylin and eosin (H&E)
staining and demyelination by Luxol fast blue (LFB) staining.
Histopathological examination was performed and scored in
a blinded fashion as follows (17): For inflammation: 0, no
inflammatory cells; 1, a few scattered inflammatory cells; 2,
organization of inflammatory infiltrates around blood vessels; 3,
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extensive perivascular cuffing with extension into parenchyma.
For demyelination: 0, none; 1, rare foci; 2, a few areas of
demyelination; and 3, large (confluent) areas of demyelination.
Scores of demyelination and inflammation were calculated by
Image-Pro Plus 6.0 software. For each mouse, three histological
sections were analyzed and their average scores were calculated.
Double-Labeling Immunofluorescence
Assay
Lumbar spinal cords were immediately harvested after extensive
perfusion on day 19 p.i., fixed with 4% paraformaldehyde, and
cut into 5-µm-slices for immunofluorescence assay. Briefly, non-
specific binding was blocked with 3% bovine serum albumin
(BSA) (Serotec, United Kingdom) and permeated with 0.3%
Triton X-100 in 1% BSA-PBS for 30 min. Slides were then
incubated with primary antibodies-mouse anti-CD4, mouse anti-
CD11b (both IgG; Proteintech, Wuhan, China), rabbit anti-
IFN-β, rabbit anti-IL-10 and rabbit anti-IL-27 (all IgG; Abcam,
Cambridge, United Kingdom) in blocking solution overnight
at 4◦C, followed by incubation with corresponding secondary
antibodies-goat anti-rabbit Cy3 conjugate (IgG; Proteintech,
Wuhan, China) and donkey anti-mouse Alexa Fluor 488
(IgG; Jackson ImmunoResearch, PA, United States) for 2 h
at room temperature. After three additional washes with PBS,
samples were counterstained with DAPI for 4′,6-diamidino-2-
phenylindole (DAPI, Roche, Basel, Switzerland), washed with
PBS and mounted. Images were captured by confocal microscope
(Olympus FluoView FV1000).
ELISA
Sera were harvested on day 19 p.i. when mice were sacrificed.
Supernatants from human monocyte cultures were harvested
after 18 h. of culture and kept at −20◦C until use. IFN-
β, IL-10, IL-27, and TNF-α concentrations were measured by
ELISA following the manufacturer’s instructions (R&D Systems,
United States). Samples were quantified by comparison with the
standard curves. Determinations were performed in duplicate in
ten samples for each group. Results were analyzed by GraphPad
Prism 6 software.
qRT-PCR
Total RNA was extracted from the spinal cord tissues
using Trizol reagent (Transgene Biotech Co., Beijing, China)
following the manufacturer’s instructions. Complementary DNA
(cDNA) synthesis was performed using Reverse Transcription
Kit (Thermo Fisher Scientific, MA, United States). Relative
quantification of target gene expression was determined by
ABI Prism R© 7500 Sequence Detection System (Biosystems, CA,
United States). Primer sequences used for IFNAR1 are listed as
follows: Forward 5′-TCCCCGCAGTATTGATGAGT-3′, Reverse
5′-CTGGTCTGTGAGCTGTACTT-3′.
Statistical Analysis
GraphPad Prism8.0 (GraphPad Software, Inc., La Jolla, CA,
United States) was used for statistical analysis. All values
are presented as mean ± SD. Comparisons between groups
were analyzed using a two-tailed Student’s t-test, one-way
ANOVA analysis of variance followed by Bonferroni correction
for measurement data, or Mann–Whitney U test for ordinal
data, as appropriate. P values less than 0.05 were considered
statistically significant.
RESULTS
MAT Alleviated Clinical Severity of EAE
Mice
Saline-treated immunized mice showed the first signs of EAE
on day 12 p.i., while the MAT-treated group did so on day 13
p.i. Mean clinical scores were significantly reduced in the MAT-
treated group compared to the saline-treated group (Figure 1A).
In order to assess EAE neuropathology, the lumbar enlargement
of spinal cords was assayed for H&E and LFB staining. Extensive
inflammatory infiltration was found in the white matter of
spinal cords of saline-treated EAE mice, and this infiltration was
significantly inhibited by MAT treatment (Figure 1B). Consistent
with inflammation, severe demyelination was also observed in the
spinal cords of the saline-treated group, and this was significantly
decreased in the MAT-treated group (Figure 1C).
MAT Induced IFN-β Production in
Periphery and the CNS
Our previous studies had shown that MAT reduced the severity
of EAE by significantly increasing serum production of IL-
10, a potent immunomodulatory cytokine (10). To define the
mechanism of MAT inducing IL-10, we examined the production
of IFN-β, one of the upstream molecules of IL-10 expression (18).
As shown in Figure 2A, while serum of saline-treated EAE mice
contained a low level of IFN-β production, this production was
significantly increased in the serum of MAT-treated EAE mice.
Further, MAT treatment significantly upregulated the expression
of type I interferon receptor (IFNAR1) in spinal cord of EAE
mice compared to saline-treated control EAE mice (Figure 2B),
indicating an enhanced IFN-β responsiveness of CNS cells.
To evaluate IFN-β expression in CNS inflamed foci after
MAT treatment, double-labeling immunofluorescence essay was
performed for IFN-β and CD11b+ cells, i.e., microglia and
infiltrating macrophages, given that this cell lineage is the
main source of IFN-β. As shown in Figures 2C,D, only a few
CD11b+IFN-β+ cells were observed in saline-treated EAE mice,
while there were greater numbers of these cells in MAT-treated
mice. The difference between these two groups was statistically
significant. We thus postulated that MAT could induce CD11b+
cells to produce IFN-β .
The Therapeutic Effect of MAT Was
Diminished by Neutralizing IFN-β mAb
To further verify the role of IFN-β production in the effect of
MAT treatment, neutralizing IFN-β mAb was used in MAT-
treated mice. Compared to the saline-treated group, the anti-
IFN-β group developed a more severe progressive disease course,
indicating a role of endogenous IFN-β production in EAE mice,
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FIGURE 1 | MAT ameliorated the severity of EAE. EAE was induced in female C57BL/6 mice by MOG35-55 + CFA. Mice received MAT treatment (150 mg/kg in
100 µl normal saline per day, i.p. injection) from day 7 to day 19 p.i., and mice that received the same volume of saline served as control. (A) Clinical score was
monitored as described in the “Materials and Methods” section. Data represent mean clinical score ± SD (n = 10 mice per group). Mice were sacrificed on day 19
p.i., and spinal cords were harvested after extensive perfusion. (B) H&E staining was performed for detection of inflammation and Luxol fast blue (FLB) staining for
demyelination. (C) Mean score of inflammation and demyelination. Data represent mean ± SD (n = 10 mice per group). ***P < 0.001.
Frontiers in Immunology | www.frontiersin.org 4 September 2020 | Volume 11 | Article 569530
fimmu-11-569530 September 24, 2020 Time: 20:8 # 5
Chu et al. Matrine Inhibited EAE by IFN-β Induction
FIGURE 2 | MAT-induced IFN-β levels in serum and in the CNS. EAE mice described in Figure 1 were sacrificed on day 19 p.i. Sera and spinal cords from each
individual mouse were harvested. (A) Serum IFN-β concentrations were measured by ELISA. (B) mRNA expression of IFNAR1 in the spinal cords was measured by
qRT-PCR. (C) IFN-β secretion of CD11b+ cells (microglia and infiltrating macrophages) in the spinal cords was determined by immunofluorescence double staining.
(D) Quantitative analysis of percentage of IFN-β+ cells among total CD11b+ cells. Values represent mean ± SD (n = 10 mice per group). ***P < 0.001.
though undetectable, as a negative feedback to control CNS
inflammation. While the mean clinical score and cumulative
clinical score were significantly reduced in the MAT-treated
group, this effect was significantly diminished after IFN-β
blockade, indicating that IFN-β induction plays a key role
in MAT treatment (Figures 3A,B). Consistent with clinical
score, HE staining showed an extensive inflammatory infiltration
in the spinal cords of EAE mice, while this infiltration was
significantly enhanced by anti-IFN-β and inhibited by MAT
treatment. Furthermore, MAT treatment was able to significantly
reduce demyelination in the CNS of EAE mice, compared to
the MAT + anti-IFN-β group (Figures 3C,D). Thus, these
observations indicate that IFN-β induction plays a key role in the
effect of MAT in EAE.
IFN-β Concentrations in the Periphery
and the CNS After MAT/Anti-IFN-β
Treatment
To confirm the effect of anti-IFN-β in MAT treatment,
serum concentrations of IFN-β were determined by ELISA,
and spinal cord tissues were examined by double-labeling
immunofluorescence essay. IFN-β levels in the sera were
significantly increased in MAT-treated mice compared to the
MAT + anti-IFN-β group, while IFN-β protein expression was
lowest in the anti-IFN-β group of mice. No significant difference
was found in the IFN-β level between sera of the saline-treated
group and MAT + anti-IFN-β group of mice (Figure 4A).
We then evaluated the effect of anti-IFN-β on IFN-β
expression in CNS inflamed foci after MAT treatment. Double-
labeling immunofluorescence essay was performed for IFN-β
and CD11b+ cells. As shown in Figures 4B,C, only a few
CD11b+IFN-β+ cells were observed in EAE mice treated with
saline or anti-IFN-β alone, while they were observed in a
larger number in MAT-treated mice. However, the numbers
of CD11b+IFN-β+ cells in the MAT + anti-IFN-β group were
significantly reduced compared to those in mice treated with
MAT alone. These data indicate that after neutralizing anti-IFN-
β antibody blocked the immunomodulatory effect of MAT on
macrophages/microglia, which produce very little IFN-β .
MAT Increased the IL-27 and IL-10
Expression
As IL-27 and IL-10 are the downstream molecules of IFN-β, we
determined the expression of IL-27 on CD11b+ cells and IL-10
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FIGURE 3 | The effect of MAT was diminished by neutralizing anti-IFN-β mAb. EAE was induced in female C57BL/6 mice by MOG35-55, and received MAT and/or
neutralizing anti-IFN-β mAb as described in the “Materials and Methods” section. Clinical score was monitored daily. (A) The mean clinical scores. Data represent
mean clinical score ± SD (n = 10 mice per group). (B) Mean cumulative clinical score obtained by adding the daily scores from the day of onset until the end of
treatment for each mouse. Data represent cumulative clinical score ± SD (n = 10 mice per group). Mice were sacrificed on day 19 p.i., and spinal cords were
harvested after extensive perfusion. (C) H&E staining was performed for detection of inflammation and Luxol fast blue (FLB) staining for demyelination. (D) Mean
score of inflammation and demyelination. Data represent mean ± SD (n = 10 mice per group). **P < 0.01, ***P < 0.001.
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FIGURE 4 | IFN-β levels in serum and in the CNS after MAT and/or anti-IFN-β mAb. Sera and spinal cord tissues from each individual mouse were harvested on day
19 p.i. (A) Concentrations of IFN-β in the sera were measured by ELISA. (B) IFN-β secretion of CD11b+ cells (microglia and infiltrating macrophages) in the spinal
cords was determined by immunofluorescence double staining. (C) Quantitative analysis of percentage of IFN-β+ cells among total CD11b+ cells. Data represent
mean ± SD (n = 10 mice per group). **P < 0.01, ***P < 0.001.
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on CD4+ cells by double-labeling immunofluorescence assay. We
found that only a few CD11b+IL-27+ cells were observed in EAE
mice treated with saline or anti-IFN-β alone, while they were
observed in a larger number in MAT-treated mice. However, the
numbers of CD11b+IL-27+ cells in the MAT + anti-IFN-β group
were significantly reduced compared to mice treated with MAT
alone (Figures 5A,B). Similarly, while the largest proportion of
CD4+IL-10+ T cells was observed in mice treated with MAT
alone, this was significantly reduced in the MAT + anti-IFN-
β group. In contrast, only small proportions of CD4+IL-10+ T
cells were observed in EAE mice treated with saline alone or
anti-IFN-β alone (Figures 5C,D).
MAT Induces IFN-β Production by
Human Monocytes
Our results showed that MAT induces IFN-β and IL-27 in
microglia and macrophages in the CNS of EAE mice. This is likely
a pathway by which MAT suppresses the clinical development
of EAE. However, from the clinical perspective, it would be
necessary to demonstrate that MAT can induce IFN-β in human
cells. To address this question, we isolated peripheral blood
CD14+ monocytes and treated them with LPS (500 ng/ml) in
the presence or absence of MAT (100 µM) for 18 h. We found
that MAT-treated monocytes had a significant increase in IFN-β
production compared to controls (Figure 6A). Moreover, MAT
induced IL-27 and IL-10 while suppressing TNF-α (Figure 6B).
These effects were dependent on IFN-β as anti-INF-β treatment
abrogated IL-27 and IL-10 production and increased TNF-α in
MAT-treated cultures (Figures 6A,B). Collectively, our data show
that MAT stimulates IFN-β production by microglia/monocytes
in mice and in human monocytes.
DISCUSSION
In the present study we demonstrate that MAT induced IFN-β
production, which promoted production IL-27 and IL-10, and
is thus a mechanism of the immunomodulatory effects of MAT
in suppressing the development of EAE. While this effect in vivo
may represent an indirect effect through its immunomodulatory
network, an in vitro study further confirmed a direct effect of
MAT on IFN-β induction.
IFN-β, a monomeric type I IFN with both antiviral and
potent anti-inflammatory effects, is also a key inducer of
IL-10 and a suppressor of Th17 differentiation (19). IFN-β
signaling is mediated through the common type I IFN receptor
and proceeds through the classic JAK/STAT signaling pathway
(20). IFN-β inhibits CCL2/CCL5 induced-T cell migration by
inhibiting p38-MAPK and ERK1/2 activation and reduces the
expression of chemokines and chemokine receptors expressed
by encephalitogenic Th1/Th17 cells, thereby decreasing their
migration into the CNS (21). It was found that sera of relapsing
remitting multiple sclerosis (RRMS) patients have a deficient
endogenous IFN-β production, as determined by an IFN-
β–reactive cell line. Endogenous IFN-β suppresses the basal
Th17 cytokine secretion of RRMS patients, and blockade of its
downstream pathway significantly diminished this effect (22).
A deficiency in secretion of endogenous IFN-β might therefore
contribute to the reduction of the Th17-mediated autoimmune
response in RRMS patients (22).
While long-term administration of high-dose recombinant
IFN-β has been a first-line MS therapy, an ideal approach would
have the capacity to enhance endogenous IFN-β production.
Indeed, several approaches have been reported to induce
endogenous IFN-β. For example, self-assembling peptides, after
being formed as immunomodulatory amyloid fibrils, effectively
suppressed EAE, with induction of a significant amount of type
1 IFN (23). IFN-β production can also be induced by certain
natural compounds. Berberine, a purified compound of the
crude extract of an anti-inflammatory herb coptis, remarkably
upregulated IFN-β expression in a breast cancer cell line, thus
demonstrating potential as a promising adjuvant for breast cancer
treatment (24). Similar results were also observed in an extract of
Huanglian (Coptidis rhizome), a widely used herb in traditional
Chinese medicine (25). While production of IFN-β and IL-10
was significantly decreased in the colonic mucosa of ulcerative
colitis rats, their production was significantly upregulated upon
herb-partitioned moxibustion (26). Fractions obtained from the
aqueous extract of B. coccineus, a plant commonly found in west
and tropical Africa, significantly stimulated IFN-β expression
in PBMCs, causing a seven-fold increase of its transcript (27).
More recently, the Bowman-Birkman Inhibitor (BBI), a soybean
derivative, was shown to induce IFN-β production, IFNAR1
gene expression, and their downstream signaling molecules, as a
mechanism underlying its suppression of EAE (15). Furthermore,
while cannabinoids suppressed EAE, this effect was dependent
on the induction of IFN-β. This was evidenced by using
R(+)WIN 55,212-2, a synthetic cannabinoid, whose inhibitory
effect on EAE was largely reduced by an anti-IFN-β mAb (28).
Consistent with these observations, we found that MAT up-
regulated IFN-β production, and its role was further verified
by IFN-β neutralizing antibody. The observation that mice
treated with anti-IFN-β alone developed more severe clinical
signs of EAE indicates an inhibitory feedback of endogenous
IFN-β production against autoimmunity. More important, the
suppressive effect of MAT on EAE was largely blocked by IFN-
β neutralizing antibody, providing strong evidence for a pivotal
role of IFN-β induction in the effect of MAT on EAE, and
making it an option for inducing endogenous IFN-β production
for MS patients.
IL-10 is an important anti-inflammatory cytokine that plays
a crucial role in preventing various inflammatory pathologies
especially in tumor and autoimmune diseases, through reducing
the function of antigen-presenting cells (29, 30), and inhibiting
T cell proliferation and Th1/Th17 cell differentiation. High IL-10
expression level within the CNS is considered important for the
initiation of recovery from EAE, and transduction of neural stem
cells with IL-10 significantly enhanced their neuroregenerative
capacity (31). Consistent with our observations, IL-10 induction
has also been considered a mechanism underlying the suppressive
effect of MAT in several other inflammatory disorders, such
as rheumatoid arthritis (32, 33), neuropathic pain (34), and
nephropathy (35). These results provide evidence for the
capacity of MAT to induce IL-10 production in inflammatory
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FIGURE 5 | MAT increased IL-27 and IL-10 expression. Spinal cord tissues from each individual mouse were harvested on day 19 p.i. IL-27 (A) secretion of CD11b+
cells and IL-10 (C) secretion of CD4+ cells in the spinal cords was determined by immunofluorescence double staining. Quantitative analysis of percentages of IL-27
(B) producing cells among total CD11b+ cells and IL-10 (D) producing cells among total CD4+ cells. Data represents mean ± SD (n = 10 mice per group).
***P < 0.001.
FIGURE 6 | MAT induced IFN-β in human monocytes. CD14+ monocytes were isolated from PBMCs of healthy donors and activated for 18 h with LPS (500 ng/ml)
in the presence or absence of Matrine (100 mM) and anti-IFN-β antibodies (20 µg/ml) or isotype control (IC). After 18 h of incubation period, supernatants were
harvested for production of IFN-β (A), IL-27, IL-10 and TNF-α (B). Bar graphs represent the mean ± SEM. Representative data from one out of three independent
experiments. *P < 0.05.
and autoimmune diseases, thus exerting its therapeutic effect
in these diseases.
Another novel finding in our study is that MAT treatment
induces IL-27 production in CD11b+ cells in the CNS, i.e.,
infiltrating macrophages/microglia. IL-27 exerts potent anti-
inflammatory effects in both infection and autoimmunity (36).
A range of cell types produce IL-27, including activated APCs,
astrocytes and microglia (37–39). Known anti-inflammatory
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effects of IL-27 include suppression of IL-2 production
(40) and Th17 differentiation (41–43). Specifically, IL-27
significantly inhibited both non-polarized and IL-23-driven IL-
17 production by myelin-reactive T cells, thereby suppressing
their encephalitogenicity in adoptive transfer EAE (37). Of
importance is that IL-27 is a potent inducer of IL-10
production (44–47), and also mediates IFN-β-induced IL-
10 (18, 44). Our results showing that MAT-treated EAE
mice had increased levels of IFN-β, IL-27 and IL-10, and
that blockade of IFN-β reduced MAT-induced IL-27 and IL-
10 production, indicate an IFN-β/IL-27/IL-10 pathway as an
important mechanism underlying the immunotherapeutic effect
of MAT on EAE.
In summary, our study demonstrates for the first time that
MAT exerts its therapeutic effect in EAE through an IFN-β/IL-
27/IL-10 pathway. MAT treatment could thus be a novel, safe,
low-cost, and effective therapy as an alternative to exogenous
IFN-β for MS.
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